Friday 19/December/2025 – 02:46 PM
The American company Ultimeon announced that its experimental drug to treat… Liver disease It achieved positive results in a mid-stage study, showing significant improvement in indicators of liver scarring and organ health after 48 weeks of treatment, sending the company’s shares up more than 15% in pre-market trading on Friday.
An experimental drug shows promise in treating liver disease
According to what was published in Reuters, Altimeon ALT.O is developing the drug bemfedotide to treat steatohepatitis associated with metabolic dysfunction (MASH), a serious disease that arises when the accumulation of fat in the liver leads to inflammation and gradual damage to its tissues.
The drug belongs to the same class of GLP-1 receptor agonists that includes popular obesity and diabetes drugs such as Novo Nordisk’s Wegovi and Ozempic, and Eli Lilly’s Mongaro and Zipbound, and is also being evaluated separately as a potential treatment for obesity.
According to the company’s statement, the results of the study, which included 212 patients, showed that taking two weekly doses of bemfedotide led to improvements in blood tests and scan-based tests, which are used to monitor liver scarring and hardening, and these improvements were greater than what was recorded after 24 weeks of treatment.
Patients who received the higher dose of 1.8 mg also lost an average of about 7.5% of their body weight over 48 weeks, with no signs of a plateau or stop in weight loss, compared to a slight decrease of only 0.2% in the placebo group.
